Article may be outdated

This article is 8 days old. Some details may have changed since publication.

CancerNetwork·3 min read·hard

Comparing Liver Cancer Prevention Strategies in Japan and the US

R
Ryosuke Tateishi, MD, PhD, FAASLD
Comparing Liver Cancer Prevention Strategies in Japan and the US
✦AI Summary

Dr. Ryosuke Tateishi discussed the differences in liver cancer prevention strategies between Japan and the US at a recent medical conference. He noted that while Japan leads in hepatitis C management, the US offers valuable insights into addressing obesity-related liver disease.

Why it matters

Cross-border medical knowledge sharing is essential for improving global health outcomes as the primary causes of liver cancer shift from viral to metabolic factors.

✦Dive DeeperCreate a free account to unlock

In an interview with CancerNetwork® at The Liver Meeting® 2026, Ryosuke Tateishi, MD, PhD, FAASLD, of the University of Tokyo, discussed what clinicians in the US and Japan can learn from each other as the leading causes of hepatocellular carcinoma (HCC) shift from viral hepatitis to metabolic dysfunction.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in